A phase Ib open-label, escalating repeat-dose trial of bavituximab (chimeric anti-phosphatidylserine monoclonal antibody) in patients co-infected with chronic hepatitis C virus and human immunodeficiency virus.

Trial Profile

A phase Ib open-label, escalating repeat-dose trial of bavituximab (chimeric anti-phosphatidylserine monoclonal antibody) in patients co-infected with chronic hepatitis C virus and human immunodeficiency virus.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2016

At a glance

  • Drugs Bavituximab (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 04 Apr 2011 Status changed from active, no longer recruiting to completed.
    • 04 Apr 2011 Results were presented at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL).
    • 01 Feb 2011 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top